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SIGNIFICANCE
Coeliac disease is a chronic enteropathy characterized by 
a permanent intolerance to gluten that is frequently as-
sociated with several extraintestinal conditions, including 
skin diseases. Dermatitis herpetiformis is the specific cu-
taneous manifestation of coeliac disease; however, many 
other dermatoses are reported in celiac patients. The im-
munopathologic hallmark of dermatitis herpetiformis is the 
presence of IgA deposits at the dermal–epidermal junction 
of perilesional skin as detected by direct immunofluores-
cence. Our study showed that such deposits can be found 
also in celiac patients with inflammatory skin diseases dif-
ferent from dermatitis herpetiformis and, therefore, could 
be considered as a marker of coeliac disease. 
Coeliac disease is an immune-mediated enteropathy 
driven by gluten, which can be associated with derma-
titis herpetiformis. The presence of granular IgA de-
posits, detected by direct immunofluorescence, is the 
hallmark of dermatitis herpetiformis; nevertheless, 
IgA deposits have also been demonstrated in healthy 
skin of patients with coeliac disease. The main objec-
tive of this study was to investigate whether IgA depo-
sits could be found in the skin of patients with coeliac 
disease who have non-dermatitis herpetiformis inflam-
matory skin diseases. Direct immunofluorescence was 
performed on perilesional skin biopsies of 6 patients 
with coeliac disease with non-dermatitis herpetifor-
mis inflammatory skin diseases and, as control, on 12 
non-coeliac patients with inflammatory skin diseases. 
IgA deposits were found in all of the patients with co-
eliac disease, but were absent in the control group. In 
conclusion, IgA deposits may be considered an immu-
nopathological marker for coeliac disease; therefore, 
patients with coeliac disease showing skin manifesta-
tions with positive direct immunofluorescence should 
be investigated carefully in order to make a differen-
tial diagnosis between dermatitis herpetiformis and 
other non-dermatitis herpetiformis inflammatory skin 
diseases.
Key words: coeliac disease; skin IgA deposits; skin manifesta-
tions of coeliac disease.
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Coeliac disease (CD) can be defined as an autoim-mune disorder where the ingestion of wheat gliadins 
and other cereal prolamins leads to demage in the small 
intestine in genetically susceptible individuals (1). The 
pathogenetic mechanism is related to a T-cell response 
against an external trigger, the gluten peptides, and to 
the ubiquitous enzyme tissue transglutaminase, which, 
as autoantigen (2), enhances the immunogenicity of 
gluten peptides (3–5).
Several extraintestinal manifestations of CD affect 
different organs and systems; among them, many muco-
cutaneous diseases have been described (6). In particular, 
dermatitis herpetiformis (DH) is considered to be a speci-
fic cutaneous manifestation of CD, although several other 
inflammatory skin diseases have been shown to be more 
frequent in patients with CD, including psoriasis, atopic 
dermatitis, alopecia areata, chronic urticaria, chronic 
ulcerative stomatitis, etc. (6).
The presence of granular IgA deposits along the ba-
sement membrane, with accentuation at the tips of the 
dermal papillae, seen on direct immunofluorescence 
(DIF) of uninvolved skin, is the pathognomonic im-
munological marker of DH (7–11). Despite minor and 
not-critical differences in the pattern, in the localization 
and in the composition of the immune deposits, due to its 
high specificity, this finding represents the gold standard 
for diagnosis of DH. 
In 2007, Cannistraci et al. (12) also showed the pre-
sence of granular IgA deposits in the healthy skin of 
patients with CD, who were not affected by any skin 
diseases, suggesting that such deposits could be con-
sidered not only a marker of DH, but, more generally, 
of CD. Thus, the main objective of this study was to 
investigate whether IgA deposits can be found not only in 
the healthy skin of patients with CD, but also in non-DH 
inflammatory skin diseases of such patients. 
METHODS
Study design
In order to assess whether IgA deposits could be found in pa-
tients with CD who have non-DH inflammatory skin diseases, a 
comparative prospective study was conducted on patients with 
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CD presenting to the immunodermatology outpatient clinic of 
our hospital. 
As control, 12 non-coeliac patients with inflammatory skin 
diseases were enrolled. The study was approved by the local 
institutional review board and was conducted according to the 
principles of the Declaration of Helsinki. All patients and controls 
provided written informed consent to participate in the study.
Patients
Patients included into the study were divided into 2 groups: (i) 
patients with CD who had non-DH inflammatory skin diseases 
(n = 6) (mean age 41 years; median age 41.5 years: male (M): 
female (F) = 0:6; F = 100%; mean duration of skin disease: 5 
years), including eczema (n = 2), atopic dermatitis, pityriasis rosea 
Gibert, granuloma annulare and lichenoid dermatitis; and (ii) non-
coeliac patients with non-DH inflammatory skin diseases (n = 12) 
as control group (mean age 34.8 years; median age 35.5 years; 
M:F = 2:10; F = 83.3%; mean duration of skin disease: 2.7 years), 
including 5 patients with psoriasis, 4 with eczema, 2 with vasculitis 
and 1 with nodular prurigo (Table I). All the inflammatory skin 
diseases were diagnosed based on clinical, histopathological and 
laboratory findings to exclude atypical variants of DH. 
All the patients were screened for CD at the Department of 
Gastroenterology at the University of Florence by antibody assay 
(anti-endomysial and IgG and IgA anti-tissue transglutaminase 
(TG) antibodies) and multiple duodenal biopsies, expressed 
according to Marsh’s classification (5) modified by Oberhuber 
(13). The most important findings of the enrolled patients in the 
groups described above are summarized in Table I. None of the 
patients with CD were on a gluten-free diet at the time of sample 
collection. 
After an accurate whole-body clinical examination and cha-
racterization of the skin manifestations presented by all enrolled 
patients in order to exclude any sign of DH, they underwent a 
cutaneous biopsy on perilesional skin to perform DIF, and le-
sional punch biopsy for histological examination to confirm the 
diagnosis of the skin disease and to exclude with certainty the 
diagnosis of DH. 
Direct immunofluorescence 
Skin samples were collected from all the patients and controls 
and immediately frozen at –80°C in liquid nitrogen. The frozen 
specimens were cut into 5-μm thick sections and 2 sections were 
layered on each slide. The slides were stored at –20°C until they 
were stained. For staining, sections were brought to room tem-
perature. Optimally diluted fluorescein isothiocyanate (FITC)-
labelled monospecific immunoglobulins (IgG, IgA, IgM, C3; 
DAKO, Copenhagen, Denmark) were layered onto the sections 
and incubated at 24°C for 30 min. Then, the sections were washed 
in phosphate-buffered saline (PBS) (pH 7.2, 0.1 M) twice and 
mounted in buffered glycerin and, finally, viewed under a Nikon 
C2 confocal microscope. The following features were documented: 
(i) composition of the immune deposits: IgG, IgA, IgM, C3; (ii) 
site of the immune deposits: dermal–epidermal junction (DEJ), 
intercellular spaces (ICS) or perivascular area; (iii) semiquantita-
tive grading of intensity of the fluorescence: from 0 (no intensity) 
to +++ (highest intensity); (iv) pattern of the immune deposits: 
granular, linear or mixed (granular/linear).





years Skin disease Histological features








DEJ PV AEA TgA (U/ml)
1 F/58 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgA, IgM, C3 IgA, IgM 3 years Yes IIIb ++ IgA: 30
IgG: 25
2 F/26 Atopic dermatitis Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgA, IgM, C3 IgA, IgM, C3 23 years Yes IIIa ++ IgA: 28
IgG: 24
3 F/42 Pityriasis rosea Gibert Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgA, C3 1 month Yes IIIc +++ IgA: 91
IgG: 75
4 F/41 Granuloma annulare Epidermis: hyp, aca, spo Dermis: 
ede, lym, mucin deposition 
IgA, IgM, C3 IgA, IgM, C3 1 year Yes IIIa ++ IgA: 23
IgG: 31
5 F/37 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgA, C3 1 year Yes IIIa + IgA: 33
IgG: 16
6 F/42 Lichenoid dermatitis DEJ: 
InfI; Kcyt
IgA, IgM, C3 IgA, C3 2 years Yes IIIb ++ IgA: 61
IgG: 54
7 F/40 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgM C3 2 years No 0 Absent Absent
8 M/50 Psoriasis Epidermis: hypP, aca, hypG
Dermis: ede; torV; lym
5 years No 0 Absent Absent
9 F/39 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
IgM, C3 1 year No 0 Absent Absent
10 M/28 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
C3 1 year No 0 Absent Absent
11 F/37 Psoriasis Epidermis: hypP, aca, hypG
Dermis: ede; torV; lym
C3, IgG IgG, IgM 1 year No 0 Absent Absent
12 F/30 Psoriasis Epidermis: hypP, aca, hypG
Dermis: ede; torV; lym
IgM, C3 IgM 4 years No 0 Absent Absent
13 F/21 Psoriasis Epidermis: hypP, aca, hypG
Dermis: ede; torV; lym
IgM, C3 2 years No 0 Absent Absent
14 F/23 Psoriasis Epidermis: hypP, aca, hypG
Dermis: ede; torV; lym
C3, C3 3 years No 0 Absent Absent
15 F/34 Vasculitis Dermis: swelling EC, FD; Neu IgM, C3 1 year No 0 Absent Absent
16 F/25 Eczema Epidermis: hyp, aca, spo Dermis: 
ede, lym
2 years No 0 Absent Absent
17 F/41 Vasculitis Dermis: swelling EC, FD; Neu C3 1 year No 0 Absent Absent
18 F/50 Nodular prurigo Epidermis:hyp, aca 1 year No 0 Absent Absent
DIF: direct immunofluorescence; DEJ: dermal-epidermal junction; PV: perivascular; AEA: anti-endomysial antibodies; tTgA: anti-tissue transglutaminase antibodies; 
hyp: hyperorthokeratosis; aca: acanthosis; spo: spongiosis; ede: oedema; lym: lymphocytes infiltrate; InfI: inflammatory infiltrate; Kcyt: keratinocytes cytolysis; hypP: 
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Confocal microscopy
Approximately 10-µm serial sections of fresh frozen skin biop-
sies from 4 out of 6 patients with CD with non DH-inflammatory 
dermatoses were investigated for IgA and epidermal TG (eTG), as 
described previously (14). Frozen sections were fixed with ice-cold 
acetone then blocked with 0.25% casein in Tris-buffered saline 
(TBS; 0.88% NaCl, ThermoFisher, 0.24% tris(hydroxymethyl) 
aminomethane, and distilled water). FITC-labelled antibodies 
against human IgA1 (Abcam, Cambridge, UK) and unlabelled 
mouse anti-human epidermal transglutaminase primary antibodies 
(Zedira, Darmstadt, Germany) were prepared in TBS containing 
1% FCS and incubated on sections for 1 h at room tempera-
ture. Secondary rabbit antibodies against mouse isotypes IgG2b 
AlexaFluor 555 (Molecular Probes, Eugene, OR, USA) at 1:200 
were prepared and incubated on sections for 1 h. Sections were 
visualized with  a Nikon C2 confocal microscope.
RESULTS
Patients with coeliac disease who have non-dermatitis 
herpetiformis inflammatory skin diseases 
All of the patients in group (i) (patients with CD who had 
non-DH inflammatory skin diseases), who presented to 
our department due to the occurrence of an inflammatory 
skin disease, had newly diagnosed CD confirmed by the 
gastroenterologist after our consultation. Detailed clini-
cal, histological and immunopathological skin features 
are shown in Table I and Figs 1–3.
None of the patients in this group had IgG deposits. 
However, granular IgA deposits along the DEJ were 
found in 6 out of 6 cases (100%), 1 of which had ac-
Fig. 1. Patient 1 with eczema. (a) Erythematous lesion with crust on the back of the hand; (b) granular IgA deposits at the dermal-epidermal junction 
found by direct immunofluorescence of perilesional skin (100×); (c–d) Compact orthokeratosis, acanthosis and spongiosis in the epidermis, subepidermal 
oedema and lymphocytes and histiocytes in the upper dermis (haematoxylin-eosin stain; c 200×, d 400×).
Fig. 2. Patient 3 with pityriasis rosea Gibert. (a) Scaly erythematous papules and plaques with collarette scaling on the trunk, abdomen and upper 
limbs. The “herald patch” on the left arm. (b) Granular IgA deposits at the dermal-epidermal junction with accentuation at the papillary tips, found by 
direct immunofluorescence of perilesional skin (400×). (c) Hyperorthokeratosis, acanthosis and spongiosis in the epidermis, perivascular lymphocytic 
and eosinophilic granulocytic infiltrate in the upper dermis. (d) Hyperorthokeratosis, acanthosis and spongiosis in the epidermis. Perivascular lymphocytic 
infiltrate in the upper dermis (haematoxylin-eosin stain; c 200×, d 400×).
Fig. 3. Patient 4 with granuloma annulare. (a) Grouped pink non-scaly papules with annular disposition on the shoulder. (b) Granular IgA deposits 
at the dermal-epidermal junction with accentuation at the papillary tips, found by direct immunofluorescence of perilesional skin (400×). (c) Compact 
orthokeratosis and acanthosis in the epidermis, interstitial areas of mucinous degeneration of collagen, lymphocytes and histiocytes in the upper dermis 
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centuation at the papillary tips; moreover perivascular 
IgA deposits were found in 4 of the patients (66.7%). 
Four out of 6 patients (66.7%) had granular IgM de-
posits along the DEJ, one of them showing accentuation 
of the deposits at the papillary tips in a DH-like pattern, 
while perivascular IgM deposits were found in 3 of the 
cases (50%).
Moreover, granular C3 deposits along the DEJ were 
found in all 6 cases (100%), with accentuation at the pa-
pillary tips in one of them, while perivascular C3 deposits 
were documented in only 3 patients (50%) (Table II).
Double-staining for the detection of both IgA and 
eTG was performed in 4 out of 6 patients with CD with 
non-DH-inflammatory dermatoses, using confocal mi-
croscopy. None of these patients presented eTG deposits 
at the dermal papillae; thus, co-localization between IgA 
and eTG could not be detected within the dermis of the 
skin specimens (Fig. 4).
Non-coeliac patients with inflammatory skin diseases
Detailed clinical, histological and immunopathological 
skin features of non-coeliac patients with inflammatory 
skin diseases are summarized in Table I. None of the 
patients in this group showed IgG deposits along the 
DEJ, while perivascular IgG deposits were present in 
only one patient (8.3%). 
Moreover, none of the patients showed IgA deposits 
at the DEJ or in the perivascular areas. In contrast, 
granular IgM deposits along the DEJ were found in 2 
out of 12 cases (16.7%) (Fig. 5), none of them showing 
accentuation at the papillary tips in a DH-like pattern; 
moreover, perivascular IgM deposits were present in 4 
patients (33.3%) (Fig. 5). 
Finally, granular C3 deposits along the DEJ could be 
detected in 5 out of 12 cases (41.7%) (Fig. 5), with no 
accentuation at the papillary tips, while perivascular C3 
deposits were also found in 5 of the 12 cases (41.7%) 
(Fig. 5, Table II). 
DISCUSSION
The most important finding of this study was the presence 
of IgA deposits at the DEJ in patients with CD with non-
DH inflammatory skin diseases.
Granular IgA deposits at the dermal papillae and/or 
along the DEJ are considered the immunopathological 
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(0) (100) (66.7) (100) (0) (66.7) (50) (50)
Group 2
(n = 12)
0 0 2 5 1 0 4 5
(0) (0) (16.7) (41.7) (8.3) (0) (33.3) (41.7)
Fig .  4 .  IgA 1  and ant i - 
transglutaminase 3 staining 
detected by confocal microscopy 
in a patient with coeliac disease. 
Granular IgA deposits were localized 
at the tips of the dermal papillae; 
anti-transglutaminase 3 antibodies 
stained the upper layers of the 
epidermis, while no transglutaminase 
3 deposits could be detected within 
the dermal papillae. No co-localization 
was found in the dermis between IgA 
and transglutaminase 3 (400×).
Fig. 5. Direct-immunofluorescence 
findings in a patient with eczema. 
(a) Granular C3 deposits at the dermal-
epidermal junction found by direct 
immunofluorescence of perilesional 
skin (400×). (b) Granular IgM deposits 
at the dermal–epidermal junction 
found by direct immunofluorescence 
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hallmark of DH, and are included within the diagnostic 
criteria of the disease as the gold standard for the diag-
nosis, due to the high sensitivity and to a specificity close 
to 100% (15). However, Cannistraci et al. (12) found IgA 
deposits in 9 patients with CD (6 on a normal diet and 
3 on a gluten-free diet) without any cutaneous diseases, 
including DH. 
The current study investigated the perilesional skin 
of patients with CD with non-DH-inflammatory skin 
diseases, using DIF, and showed the presence of IgA de-
posits at the DEJ in all the tested patients. Therefore, IgA 
deposits might be considered not only as a distinct feature 
of DH, but, more in general, as an immunopathological 
marker of CD that could even have a diagnostic role for 
the disease. Thus, none of the non-coeliac patients in 
the control group had IgA deposits, confirming the high 
specificity of such a finding.
The low number of patients included is a major 
limitation of this study, hindering statistical analysis. 
However, although further studies should be performed 
to confirm our hypothesis, our study raised an important 
point about the differential diagnosis of skin diseases in 
patients with CD. 
As a consequence, several cases of clinically atypical 
DH reported in the literature that were diagnosed based 
only on DIF findings should be critically revised. Among 
them, purpuric and petechial lesions on the palmo-plantar 
surfaces or the fingertips (16–21), palmoplantar keratosis 
(22), wheals of chronic urticaria (23) and lesions mimick-
ing prurigo pigmentosa (24) in the absence of clinical and 
histopathological findings suggestive for DH could be 
better diagnosed as IgA-positive dermatoses in patients 
with CD, rather than as true DH.
The current study also raises some questions about 
the pathogenetic role of IgA deposits in DH. Recently 
Görög et al. (25), employing a newly developed sandwich 
enzyme-linked immunoassay (ELISA) on the plasma and 
serum, demonstrated the presence of circulating IgA-
TG3 immunocomplexes in patients with CD who were 
affected by DH, that disappeared when they adopted a 
gluten-free diet. Moreover, IgA-containing immunocom-
plexes were found also in patients with CD without DH 
(26). In patients with DH, the dermal deposition of these 
circulating immunocomplexes is thought to trigger che-
motaxis and activation of neutrophils, with consequent 
development of skin lesions. 
By contrast, in our case-series as well as in patients 
with CD without any skin lesions, the amounts of such 
deposits may be not enough to trigger the inflammatory 
response. Therefore, other pathogenetic factors may play 
a role in such a process, such as the deposition of eTG at 
the dermal papillae, which was not found in our patients.
Regarding the other kind of deposits found at DIF in 
our investigation, the presence of C3 at the DEJ may 
be related to the activation of innate immunity. Indeed, 
recent evidence regarding CD has increasingly shown 
the role of innate immunity in triggering the immune 
response by stimulating the adaptive immune response 
and by mucosal damage. The interaction between the 
gut microbiota and the mucosal wall is mediated by the 
same receptors, which can activate innate immunity. 
Thus, changes in gut microbiota may lead to activation 
of this inflammatory pathway (27, 28). 
By contrast, IgM or C3 deposits, which were found 
in some of the patients in the control group, should be 
considered non-specific, as it is not uncommon to detect 
these deposits in the skin of patients with inflammatory 
diseases, such as psoriasis, that may be more evident in 
sun-exposed areas (29). 
In conclusion, this study showed that DH-like IgA 
deposits in the skin may represent an immunopatholo-
gical marker of CD, which might play a diagnostic role 
if confirmed in larger series. 
Moreover, this study also raises some questions about 
the diagnosis of DH, since granular IgA deposits along 
the DEJ can also be found in perilesional skin of patients 
with CD with skin diseases different from DH. Thus, 
the diagnosis of DH should be the result of an overall 
assessment, including clinical, histological and immu-
nopathological findings. This may be important for the 
management of the patients; in fact, whilst a gluten-free 
diet should be used in all patients with CD, a medication 
such as dapsone would be effective only in patients with 
DH and, therefore, the need for a correct diagnosis in this 
setting becomes paramount.
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